open access

Vol 11, No 4 (2007)
REVIEV
Published online: 2007-09-07
Get Citation

The renin-angiotensin-aldosterone system - new pathogenetic and therapeutic aspects Part 2. Aldosterone - important inductor of pathogenetic pathways damaging the cardiovascular system and kidneys

Lidia Hyla-Klekot, Barbara Pulcer, Franciszek Kokot
Nadciśnienie tętnicze 2007;11(4):357-363.

open access

Vol 11, No 4 (2007)
REVIEV
Published online: 2007-09-07

Abstract

Participation of aldosterone in the pathogenesis of vascular fibrosis, glomerulosclerosis, progression of different glomerulopathies and heart muscle remodelling in hypertensive patients has already been proven, both in clinical and experimental studies. This fact was the reason why aldosterone antagonists or blockers of mineralocorticosteroid receptors (MR) became important drugs used in prevention or/and treatment of cardiovascular injuries in hypertensive patients and in patients with chronic renal glomerulopathies. Most of the damaging effects of aldosterone are induced by stimulation of the MRs and expression of the MDM2 gene (genomic pathway), by stimulation of proinflammatory cytokines and by generation of reactive oxygen species - ROS (nongenomic pathway). These injuring effects of aldosterone can be prevented or attenuated by using specific or nonspecific aldosterone antagonists. Therapeutic benefits of aldosterone treatment have already been proven in patients with diabetic nephropathy and other glomerulopathies, in postacute myocardial infarction patients and in patients with active atherosclerotic vascular lesions. Thus aldosterone antagonists seem to be important components of contemporary therapeutic strategies used in hypertensive patients and patients with kidney diseases. Arterial Hypertension 2007, vol. 11, no 4, pages 357-363.

Abstract

Participation of aldosterone in the pathogenesis of vascular fibrosis, glomerulosclerosis, progression of different glomerulopathies and heart muscle remodelling in hypertensive patients has already been proven, both in clinical and experimental studies. This fact was the reason why aldosterone antagonists or blockers of mineralocorticosteroid receptors (MR) became important drugs used in prevention or/and treatment of cardiovascular injuries in hypertensive patients and in patients with chronic renal glomerulopathies. Most of the damaging effects of aldosterone are induced by stimulation of the MRs and expression of the MDM2 gene (genomic pathway), by stimulation of proinflammatory cytokines and by generation of reactive oxygen species - ROS (nongenomic pathway). These injuring effects of aldosterone can be prevented or attenuated by using specific or nonspecific aldosterone antagonists. Therapeutic benefits of aldosterone treatment have already been proven in patients with diabetic nephropathy and other glomerulopathies, in postacute myocardial infarction patients and in patients with active atherosclerotic vascular lesions. Thus aldosterone antagonists seem to be important components of contemporary therapeutic strategies used in hypertensive patients and patients with kidney diseases. Arterial Hypertension 2007, vol. 11, no 4, pages 357-363.
Get Citation

Keywords

aldosterone; aldosterone antagonists; aldosterone - inductor of important pathogenetic pathways

About this article
Title

The renin-angiotensin-aldosterone system - new pathogenetic and therapeutic aspects Part 2. Aldosterone - important inductor of pathogenetic pathways damaging the cardiovascular system and kidneys

Journal

Arterial Hypertension

Issue

Vol 11, No 4 (2007)

Pages

357-363

Published online

2007-09-07

Bibliographic record

Nadciśnienie tętnicze 2007;11(4):357-363.

Keywords

aldosterone
aldosterone antagonists
aldosterone - inductor of important pathogenetic pathways

Authors

Lidia Hyla-Klekot
Barbara Pulcer
Franciszek Kokot

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl